Acuta Capital Partners LLC Sells 101,330 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Acuta Capital Partners LLC lessened its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 25.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 296,368 shares of the company’s stock after selling 101,330 shares during the quarter. Enliven Therapeutics comprises approximately 6.1% of Acuta Capital Partners LLC’s investment portfolio, making the stock its 5th biggest holding. Acuta Capital Partners LLC owned approximately 0.63% of Enliven Therapeutics worth $7,569,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Quest Partners LLC grew its stake in shares of Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Enliven Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after buying an additional 3,559 shares during the last quarter. SG Americas Securities LLC bought a new position in Enliven Therapeutics in the 3rd quarter valued at $256,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at $322,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of Enliven Therapeutics by 25.6% during the third quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock worth $441,000 after acquiring an additional 3,518 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Stock Up 4.4 %

ELVN stock opened at $25.41 on Thursday. Enliven Therapeutics, Inc. has a twelve month low of $9.80 and a twelve month high of $30.03. The company has a market cap of $1.24 billion, a P/E ratio of -13.37 and a beta of 1.08. The business’s fifty day moving average is $26.71 and its 200-day moving average is $24.12.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ELVN shares. Robert W. Baird lifted their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Insider Buying and Selling at Enliven Therapeutics

In related news, CEO Samuel Kintz sold 12,206 shares of the business’s stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $27.51, for a total transaction of $335,787.06. Following the completion of the transaction, the chief executive officer now owns 1,036,523 shares in the company, valued at approximately $28,514,747.73. The trade was a 1.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joseph P. Lyssikatos sold 847 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $30.00, for a total transaction of $25,410.00. Following the completion of the sale, the insider now owns 1,015,188 shares in the company, valued at approximately $30,455,640. This trade represents a 0.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 123,945 shares of company stock valued at $3,451,099. 29.20% of the stock is currently owned by company insiders.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.